<DOC>
	<DOCNO>NCT00060502</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety infliximab , active ingredient Remicade , treatment cachexia pancreatic cancer patient receive chemotherapy gemcitabine .</brief_summary>
	<brief_title>A Study Safety Effectiveness Infliximab ( Remicade ) Patients With Pancreatic Cancer Related Cachexia</brief_title>
	<detailed_description>Cachexia condition occur cancer patient chronically ill patient characterize rapid loss fatty tissue skeletal muscle . The key feature condition weight loss , symptom , anorexia ( loss appetite ) , fatigue , vomit anemia ( low number red blood cell ) may also occur.The purpose study evaluate effectiveness safety infliximab , active ingredient Remicade , treatment cachexia pancreatic cancer patient receive chemotherapy gemcitabine . In cycle 1 ( 8wks ) , patient receive weekly infusion gemcitabine wk 0 6 infusion infliximab placebo wks 0 , 2 , 4 . For additional cycle , patient receive infusion gemcitabine first 3wks infliximab placebo wk 0 4 wk cycle maximum 5 cycle . Patients stable disease may receive extend dose qualified.Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . In cycle 1 ( 8wks ) , patient receive weekly infusion gemcitabine wk 0 6 infusion infliximab placebo wks 0 , 2 , 4 . For additional cycle , patient receive infusion gemcitabine first 3wks infliximab placebo wk 0 4 wk cycle maximum 5 cycle .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients must document diagnosis pancreatic cancer newly diagnose Patients must document loss &gt; =10 % body weight compare weight prior diagnosis , &gt; =5 % weight loss within 90 day prior randomization Patients must Karnofsky performance status 70 100 eligible accord country specific tuberculosis ( TB ) screening rule . Patients must receive previous chemotherapy , biologic therapy radiation therapy pancreatic cancer Patients must history current evidence active TB , skin test screen evidence latent TB , history treat TB , active latent Patients must evidence history congestive heart failure Patients must opportunistic infection within 6 month prior screen Patients must pregnant , nurse plan pregnancy Patients must ongoing use tube feeding TPN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>cachexia</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>infliximab</keyword>
	<keyword>anorexia</keyword>
	<keyword>anemia</keyword>
	<keyword>Remicade .</keyword>
</DOC>